Back to News
Market Impact: 0.18
BlossomHill Therapeutics Average Analyst Price Target Raised 10.53% to $37.48
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for BlossomHill Therapeutics was raised 10.53% to $37.48 per share from $33.92 on September 11, 2026. The upward revision signals modestly improved analyst expectations, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.22
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October